ADC Therapeutics SA 8-K

What Happened
ADC Therapeutics SA filed an 8-K (July 2, 2026) disclosing that its Board, with advice from its independent compensation consultant, approved one-time retention awards on June 30, 2026 for several employees, including named executives. Awards combine cash payments and restricted stock units (RSUs) for: Ameet Mallik (CEO), Jose Carmona (CFO) and Mohamed Zaki (CMO). The cash portion is scheduled to be paid on or about July 15, 2026 and the RSUs were granted June 30, 2026.

Key Details

• Total cash awards: $2,906,316 (CEO $1,795,500; CFO $541,842; CMO $568,974).
• Total RSUs granted: 1,092,600 RSUs (CEO 675,000; CFO 203,700; CMO 213,900).
• Cash is subject to repayment if the executive leaves before June 30, 2027, except if terminated by the company without cause or the executive resigns for good reason.
• RSUs vest on the earlier of June 30, 2027 or termination by the company without cause / resignation for good reason, subject to continued employment on the vesting date. Incentive Award Agreements will be filed with the Company’s Form 10-Q for the quarter ended June 30, 2026.

Why It Matters
These retention awards are intended to keep senior management in place through mid‑2027. For investors, the items to note are the near‑term cash outflow (~$2.9M) and potential equity dilution from ~1.09M RSUs if they vest and convert to shares. The awards could increase compensation expense and impact share count if RSUs vest, but repayment and vesting conditions limit payouts if executives leave voluntarily without qualifying reasons.